Knight Therapeutics Inc. (GUD)

Review of Knight Therapeutics

SEP 21, 2023 - The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).

Download Report

Q: HI,
I dont have any credits and if you can assist in answering the question would appreciate it. Is CSU, LMN, and TOI still buys at today's prices . At this point, Is Knight worth holding? Thanks for your service

Read Answer Asked by umedali on May 14, 2025

Knight Therapeutics Inc. (GUD)

Q: Your thoughts on GUD going forward in light of:

07:20 AM EDT, 03/24/2025 (MT Newswires) -- Knight Therapeutics (GUD.TO) overnight Sunday said G252 Capital has disposed of 2.5 million of its shares at $6.30 each, and no longer holds over 10% of Knight's outstanding shares.

G2S2 now owns 7.54 million Knight shares, for a 7.6% stake.

Does this limit upside of the stock price?

Read Answer Asked by Michael on March 25, 2025

Q: Hello,
What do you think of Knight's results? In the cannabis space, would be a good idea to start a position in Aurora and Cronos Group. Both seem to have a decent PE (based on yahoo) or is still too early given US may not legalize it. Alternatively, do you think it is best to go with HMMJ but many companies in the ETF do not have profits so am wondering best way to enter the space.. much appreciated.

Read Answer Asked by umedali on March 21, 2025